Sanofi Revenue 2010-2024 | SNY
Sanofi annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Sanofi revenue for the quarter ending September 30, 2024 was $15.567B, a 12.64% increase year-over-year.
- Sanofi revenue for the twelve months ending September 30, 2024 was $53.031B, a 8.22% increase year-over-year.
- Sanofi annual revenue for 2023 was $50.266B, a 5.11% increase from 2022.
- Sanofi annual revenue for 2022 was $47.822B, a 3.18% increase from 2021.
- Sanofi annual revenue for 2021 was $46.348B, a 8.58% increase from 2020.
Sanofi Annual Revenue
(Millions of US $) |
| 2023 |
$50,266 |
| 2022 |
$47,822 |
| 2021 |
$46,348 |
| 2020 |
$42,687 |
| 2019 |
$42,147 |
| 2018 |
$42,135 |
| 2017 |
$40,921 |
| 2016 |
$38,408 |
| 2015 |
$38,710 |
| 2014 |
$45,341 |
| 2013 |
$44,240 |
| 2012 |
$46,244 |
| 2011 |
$48,829 |
| 2010 |
$42,539 |
| 2009 |
$42,883 |
Sanofi Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$15,567 |
| 2024-06-30 |
$12,255 |
| 2024-03-31 |
$12,071 |
| 2023-12-31 |
$13,138 |
| 2023-09-30 |
$13,821 |
| 2023-06-30 |
$11,648 |
| 2023-03-31 |
$11,660 |
| 2022-12-31 |
$11,876 |
| 2022-09-30 |
$13,233 |
| 2022-06-30 |
$11,432 |
| 2022-03-31 |
$11,281 |
| 2021-09-30 |
$12,770 |
| 2021-06-30 |
|
| 2021-03-31 |
$10,713 |
| 2020-09-30 |
$11,548 |
| 2020-03-31 |
$10,277 |
| 2019-09-30 |
$11,032 |
| 2019-03-31 |
$9,896 |
| 2018-03-31 |
$9,988 |
| 2017-12-31 |
$10,572 |
| 2017-09-30 |
$11,040 |
| 2017-06-30 |
$9,828 |
| 2017-03-31 |
$9,482 |
| 2016-12-31 |
$9,904 |
| 2016-09-30 |
$10,373 |
| 2016-06-30 |
$9,385 |
| 2016-03-31 |
$8,746 |
| 2015-09-30 |
$10,770 |
| 2015-06-30 |
$10,466 |
| 2014-06-30 |
$11,175 |
| 2013-06-30 |
$10,560 |
| 2012-06-30 |
$11,716 |
| 2012-03-31 |
$11,247 |
| 2011-12-31 |
$11,701 |
| 2011-09-30 |
$12,087 |
| 2011-06-30 |
$12,061 |
| 2011-03-31 |
$11,423 |
| 2010-12-31 |
$10,075 |
| 2010-09-30 |
$10,788 |
| 2010-06-30 |
$10,648 |
| 2010-03-31 |
$9,748 |
| 2009-12-31 |
$10,098 |
| 2009-09-30 |
$10,922 |
| 2009-06-30 |
$10,582 |
| 2009-03-31 |
$9,190 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$135.190B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
